Compare Sezzle Inc (SEZL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Sezzle Inc trades at $118.15 (market cap $3.94B), while Vertex Pharmaceuticals Incorporated trades at $520 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 34× Sezzle Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| SEZL | VRTX | |
|---|---|---|
Market Cap | $3.94B | $134.06B |
Sector | Technology | Health |
52-Week High | $188.55 | $557.96 |
52-Week Low | $50.97 | $376.62 |
Enterprise Value | $3.99B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEZL trades at $118.35, down 1.85% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals, including a 30.35% net income margin and consistent earnings beats in recent quarters. Recent news highlights expansion of its merchant network with brands like Gymshark and the launch of Sezzle Send, aiming to drive growth beyond traditional BNPL services.
The outlook remains positive with a consensus price target of $161.17, implying 36% upside, supported by robust profitability and strategic initiatives. Key risks include competitive pressures in fintech, reliance on BNPL adoption, and market volatility. Analyst sentiment is bullish with 67% buy ratings, but investors should monitor execution of new growth channels and macroeconomic impacts on consumer spending.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
